Cobra Biologics and Symbiosis Pharmaceutical Services have successfully completed their collaboration to develop synergistic capabilities intended to accelerate the clinical and commercial production of viral vectors. The 18-month joint project saw a combined investment of £4.8 million, including significant support from a grant received under the UK Governments’ Innovate UK Health and Life Sciences Program.    The collaboration significantly increases both companies’ existing commercial capac...